{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=100",
    "query": {
      "intervention": "Control Study Product",
      "page": 100
    },
    "page_size": 10
  },
  "pagination": {
    "page": 100,
    "page_size": 10,
    "total_count": 4247,
    "total_pages": 425,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=101&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=99&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T07:58:24.417Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01792830",
      "title": "Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Poor Glycemic Control"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Glargine insulin",
          "type": "DRUG"
        },
        {
          "name": "Glulisine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 175,
      "start_date": "2012-10",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2018-09-24",
      "last_synced_at": "2026-11-08T07:58:24.417Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01792830"
    },
    {
      "nct_id": "NCT05228834",
      "title": "Voxelotor Neurocognitive Function Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Voxelotor Only Product in Oral Dose Form",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "8 Years to 18 Years"
      },
      "enrollment_count": 1,
      "start_date": "2022-06-24",
      "completion_date": "2022-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-11-08T07:58:24.417Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05228834"
    },
    {
      "nct_id": "NCT03025698",
      "title": "A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "hATG",
          "type": "DRUG"
        },
        {
          "name": "CsA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 51,
      "start_date": "2017-09-30",
      "completion_date": "2025-01-27",
      "has_results": true,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-11-08T07:58:24.417Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03025698"
    },
    {
      "nct_id": "NCT05646719",
      "title": "Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "Phentolamine Opthalmic Solution 0.75%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Low dose pilocarpine",
          "type": "DRUG"
        },
        {
          "name": "Low dose pilocarpine vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Opus Genetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "40 Years to 64 Years"
      },
      "enrollment_count": 333,
      "start_date": "2022-12-22",
      "completion_date": "2023-10-11",
      "has_results": true,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-08T07:58:24.417Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Azusa, California • Newport Beach, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05646719"
    },
    {
      "nct_id": "NCT05282771",
      "title": "A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%",
          "type": "DRUG"
        },
        {
          "name": "Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 402,
      "start_date": "2021-04-16",
      "completion_date": "2022-02-10",
      "has_results": false,
      "last_update_posted_date": "2022-03-16",
      "last_synced_at": "2026-11-08T07:58:24.417Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05282771"
    },
    {
      "nct_id": "NCT05174559",
      "title": "Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Phenylketonurias"
      ],
      "interventions": [
        {
          "name": "PreKUnil® LNAA Medical Food for PKU",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-09-01",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2023-12-04",
      "last_synced_at": "2026-11-08T07:58:24.417Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05174559"
    },
    {
      "nct_id": "NCT03162796",
      "title": "A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Psoriatic"
      ],
      "interventions": [
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 383,
      "start_date": "2017-08-24",
      "completion_date": "2019-11-18",
      "has_results": true,
      "last_update_posted_date": "2021-02-03",
      "last_synced_at": "2026-11-08T07:58:24.417Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03162796"
    },
    {
      "nct_id": "NCT06919289",
      "title": "The Investigators Are Comparing Lidocaine and Papaverine Nerve Blocks to Determine Which Improves Blood Flow Better, Making the \"Phoenix Sign\" Clearer on Imaging. This Helps Accurately Diagnose Nerve Compression, Improving Patient Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Drop Foot"
      ],
      "interventions": [
        {
          "name": "Infiltration of papaverine",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine infiltration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Neuropathy Centers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 4,
      "start_date": "2024-03-07",
      "completion_date": "2024-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-09",
      "last_synced_at": "2026-11-08T07:58:24.417Z",
      "location_count": 1,
      "location_summary": "Jasper, Indiana",
      "locations": [
        {
          "city": "Jasper",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06919289"
    },
    {
      "nct_id": "NCT05129618",
      "title": "Tolerability Study of Panosyl Isomaltooligosaccharides (PIMO), in Subjects With Chronic Idiopathic Constipation (CIC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Constipation Chronic Idiopathic"
      ],
      "interventions": [
        {
          "name": "MHS 1031",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Microbiome Health Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 172,
      "start_date": "2021-09-23",
      "completion_date": "2022-06-12",
      "has_results": false,
      "last_update_posted_date": "2023-07-18",
      "last_synced_at": "2026-11-08T07:58:24.417Z",
      "location_count": 1,
      "location_summary": "Manassas, Virginia",
      "locations": [
        {
          "city": "Manassas",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05129618"
    },
    {
      "nct_id": "NCT04709913",
      "title": "Multiple Ascending Dose Study of HU6 in High BMI Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "HU6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rivus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-01-04",
      "completion_date": "2021-07-30",
      "has_results": false,
      "last_update_posted_date": "2021-08-16",
      "last_synced_at": "2026-11-08T07:58:24.417Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04709913"
    }
  ]
}